Amarin Pharmaceuticals Ireland Ltd.

To evaluate the pharmacokinetic (PK) characteristics of plasma and red blood cell EPA after 28 consecutive days of oral administration of Vascepa capsules in healthy Chinese subjects and the safety of 28 consecutive days of oral administration of Vascepa capsules

The primary objective of this study is to evaluate the efficacy of ICOSAPENT ETHYL (IPE) 4 g/day or 2 g/day compared with placebo in reducing fasting TG levels in subjects with fasting TG levels ≥500 mg/dL and ≤2000 mg/dL (≥5.6 mmol/L and ≤22.6 mmol/L). The secondary objectives of this study are as follows: 1. To evaluate the safety and tolerability of ICOSAPENT ETHYL (IPE) 4 g/day treatment; 2. To evaluate the safety and tolerability of ICOSAPENT ETHYL (IPE) 2 g/day treatment; 3. To evaluate the effect on very low-density lipoprotein cholesterol (VLDL-C); 4. To evaluate the effect on apolipoprotein B (apo B);